R egulatory T cells (Tregs 3 /CD4
ϩ FOXP3 ϩ T cells) have now been shown to play critical roles in all aspects of normal and pathologic immune responses (1, 2). They are central to the maintenance of self-tolerance and the prevention of autoimmunity. A detailed cellular and molecular understanding of their mechanism of action would provide a strong foundation for manipulating their function therapeutically. Numerous mechanisms have been proposed to explain the suppressive functions of Tregs, but none appears to be unifying (3, 4). Most studies have used an in vitro coculture assay developed by us (5) and others (6) as the major experimental tool. Proposed mechanisms have included secretion of suppressor cytokines (IL-10, TGF-␤, IL-35) (7-9), CTLA-4/CD80-CD86 interactions (10 -13) , transfer of cAMP from suppressors to responders via gap junctions (14) , generation of adenosine (15) , IL-2 consumption (16, 17) , and cell contact-mediated suppression by a yet uncharacterized membrane molecule. Although Transwell experiments suggest that the suppressive activity of Tregs is cell contact dependent, the secretion of short-range mediators has not been ruled out. A considerable controversy also exists regarding the cellular target for Treg-mediated suppression. Some studies have strongly supported a Treg-T responder cell interaction (18, 19) , while others favor a Treg-APC interaction (20, 21) . Lastly, the relationship between any of the in vitro properties of Tregs and their in vivo behavior also has been challenged (22) . For example, although Tregs are nonresponsive to TCR stimulation in vitro, they proliferate in a fashion indistinguishable from conventional CD4 ϩ T cells upon TCR activation in vivo.
Although there are several studies addressing the target cells and the role of IL-2 and LFA-1 on mouse Tregs, the characterization of human Tregs is limited. A detailed understanding of the primary target cell and the adhesion molecules involved in Treg cell contact-mediated suppression would provide a valuable opportunity to design therapeutic methods for manipulating Treg function. One of the major obstacles to defining the molecules involved in Tregtarget cell interaction is that adhesion molecules, such as LFA-1/ ICAM-1, are also necessary for the interaction of responder T cells with APCs. Therefore, blocking integrins such as LFA-1 in an in vitro suppression assay would affect the activation of the responder cells and the ability to measure suppression. Moreover, neutralization of IL-2 or blocking the IL-2 receptor in the conventional human suppression assay would not permit the analysis of the role of IL-2 in Treg-mediated suppression, since it would affect the activation of the responder cells. To circumvent these obstacles, we have developed a novel in vitro suppression assay consisting of human (h) Tregs as suppressors and mouse (m) CD4 ϩ CD25 Ϫ T cells and APCs as responders. We demonstrate that suppression of T cell activation across the species is highly efficient in vitro, is cell contact dependent, and is not mediated by IL-10 or TGF-␤. Importantly, we define a critical role for LFA-1(CD11a-CD18)/ ICAM-1(CD54) interactions in human Treg function. Use of responder CD4 ϩ T cells from mice deficient in ICAM-1 expression demonstrated that human LFA-1 specifically interacts with ICAM-1 on the mouse dendritic cells (DCs) rather than on the responder T cells and that this interaction is sufficient for suppression of T cell activation. Because activated human T cells respond poorly to mouse IL-2, this assay system also allowed us to determine the requirements for IL-2 in the activation of Treg suppressor function and the contribution of IL-2 consumption to Treg-mediated suppression. These results provide new insights into the cell surface Ags, cellular targets, and cytokines involved in human Treg-mediated, cell contact-dependent suppression and offer a potential therapeutic approach to both augment and reverse Treg suppressor function.
Materials and Methods
Mouse cell purification C57BL/6, BALB/c, and ICAM-1 Ϫ/Ϫ mice were purchased from The Jackson Laboratory. Hemagglutinin (HA)-TCR-transgenic (Tg) mice were maintained at Taconic Farms under a National Institute of Allergy and Infectious Diseases (NIAID) contract. Mice were used at 6 -10 wk of age and housed under specific pathogen-free conditions in the NIAID animal facility in accordance with institutional guidelines. The CD4 
Human cell purification
Peripheral blood was obtained from healthy adult donors through the National Institutes of Health Department of Transfusion Medicine (Bethesda, MD). Leukocyte adhesion deficiency type 1 (LAD-1) patients were enrolled on protocol 93-I-0119 approved by the NIAID Institutional Review Board. The entire clinical investigation was conducted and informed consent was obtained from all patients in accordance with the Declaration of Helsinki. PBMCs were prepared over Ficoll-Paque Plus gradients (GE Healthcare). The CD4 ϩ cells were enriched over the AutoMACS by positive selection with human CD4 microbeads (Miltenyi Biotec). The cells were labeled with CD4 FITC, CD127 PE (both BD Biosciences), and CD25 PE-Alexa Fluor 700 (Invitrogen), then FACS sorted with the FACSVantage DiVa or FACSAria flow cytometer (BD Biosciences) for CD4 ϩ CD25 Ϫ , CD4 ϩ CD25 int , and CD4 ϩ CD127 Ϫ CD25 high . The purity of the Tregs was assessed by fixing and permeabilizing the cells with a Fixation/Permeabilization kit and staining for FOXP3 with anti-FOXP3 Alexa Fluor 647 mAb clone 236A/E7 (all from eBioscience). Human APCs were obtained by depleting T cells from PBMCs with CD3 microbeads (Miltenyi Biotec) using the AutoMACS deplete-sensitive program and irradiating at 4000 rad. ϩ CD127 Ϫ CD25 high (hCD25 high ), hCD25 int , hCD25 Ϫ or mouse mCD25 ϩ T cells. In the assay, the mouse CD25 Ϫ and CD25 ϩ were activated with mouse APCs and soluble anti-mCD3, while the human cells were activated with plate-bound anti-hCD3 (5 g/ml) and anti-hCD28 (2.5 g/ml) in the cocultures. ϩ CD25 Ϫ T cells with preactivated hTregs at 1:0, 1:1, and 4:1 ratios of mouse responder to hTreg in the presence of isotype control or neutralizing mAbs to TGF-␤ (anti-TGF␤), hIL-10 (anti-hIL10), mouse IL-10 receptor (mIL10R), and human CTLA-4 (anti-hCTLA4). rhLAP also was used to neutralize TGF-␤. Data are representative of three independent experiments.
Antibodies
Anti-human CD25 mAb (daclizumab; Roche) was used at 25 g/ml. For neutralization of IL-10 and TGF-␤, 25 g/ml anti-hIL-10 (25209; R&D Systems), 25 g/ml anti-mIL-10R (1B1.3a; BD Biosciences), 50 g/ml anti-TGF-␤ (1D11; R&D Systems), or 5 g/ml recombinant human latency-associated peptide (rhLAP; R&D Systems) were used. For blocking CTLA-4, 25 g/ml anti-human CTLA-4 was used (BNI3; BD Biosciences). For blocking CD11a, CD18, and ICAM, 10 g/ml were used for anti-human CD11a (38 and MEM-83 from Genetex; efalizumab from Genentech), anti-human CD18 (TS1/18; BioLegend and MEM-48; Genetex), anti-human ICAM-1 (15.2, Genetex), anti-human ICAM-2 (CBR-IC2/2; Abcam), anti-human ICAM-3 (76205; R&D Systems), and anti-mouse ICAM-2 (3C4; BD Biosciences).
In vitro suppression assay
For optimal stimulation of fresh hTregs, 96 flat-bottom culture plates (Nunc) were coated overnight with 5 g/ml anti-human CD3 (UCHT1) and 2.5 g/ml anti-human CD28 (both eBioscience). For suboptimal stimulation of hTregs, 3 g/ml anti-CD3 and 1 g/ml anti-CD28 were plate bound. For suppression of mouse responders, CD4 ϩ CD25 Ϫ or CD8 ϩ CD25 Ϫ cells (5 ϫ 10 4 ) were cultured with irradiated mouse Tdepleted splenocytes as APCs (5 ϫ 10 4 ) or mouse splenic DCs (5 ϫ 10 3 ; 10:1 mouse CD4:DC ratio) and 0.25 g/ml soluble anti-mouse CD3 (145-2C11; eBioscience) for 72 h in the presence of varying numbers of fresh hTregs or preactivated hTregs. In this coculture, the fresh hTregs were activated with plate-bound anti-hCD3/CD28 as described above, while the mouse responders were activated with APCs/DCs and soluble anti-mCD3. hTregs were preactivated by stimulation for 48 h with plate-bound 5 g/ml UCHT1, 2.5 g/ml anti-CD28, and 100 U/ml rhIL-2 (PeproTech), washed, and used in the suppression assay without restimulation. mTregs were preactivated by stimulation for 48 h with plate-bound anti-mCD3 (2 g/ml), anti-mCD28 (2 g/ml), and 100 U/ml rhIL-2, washed, and used in the suppression assay without restimulation. For suppression of human responders, 5 ϫ 10 4 CD4
ϩ CD25 Ϫ cells were cultured in 96 flat-bottom culture plates with irradiated human APCs (5 ϫ 10 4 ) and 0.25 g/ml soluble OKT3 for 72 h in the presence of varying numbers of fresh hTregs, fresh mTregs, or preactivated mTregs. Fresh mTregs in the cocultures were activated with plate-bound 2 g/ml anti-mCD3 and 1 g/ml anti-mCD28 (eBioscience). Proliferation was measured in triplicates by the incorporation of tritiated thymidine over the last 6 -8 h of the coculture. All cells were cultured in complete medium (RPMI 1640 supplemented with 10% heat-inactivated FCS (Atlanta Biologicals), 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, 10 mM HEPES, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate (all BioSource International), and 50 M 2-ME (Sigma-Aldrich)).
Mouse splenic DCs assay
The splenic DCs were obtained from spleens by fragmenting and digesting for 30 min at 37 o C in complete medium containing liberase blendzyme II and 2 g/ml DNase (Roche). The DCs were isolated with CD11c microbeads (Miltenyi Biotex) over the AutoMACS using the posseld2 program. The purity was Ͼ95% based on CD11c allophycocyanin staining (BD Biosciences). Two ϫ 10 5 DCs were cultured with complete medium in 24-well culture plate (Corning) for 18 h alone or with 1 ϫ 10 6 preactivated hCD25 high or hCD25 Ϫ cells. The level of CD80/CD86 on the DCs was detected by flow cytometry with a BD Biosciences FACSCalibur after staining with CD80 FITC, CD86 PE, and CD11c allophycocyanin (BD Biosciences). All flow cytometric data were analyzed with FlowJo (Tree Star). To test the function of the DCs after 18 h of culture, the DCs were washed with complete medium containing 0.1 M EDTA to disrupt any DC-T cell complexes and positively selected with CD11c microbeads over the AutoMACS. 
Results

hTregs suppress mouse T cell activation
To investigate whether hTregs could suppress the activation of mCD4 ϩ CD25 Ϫ responder T cells, we FACS-sorted human CD4 and CD25, while the human CD4 ϩ CD25 Ϫ and CD4 ϩ CD25 int cells had no effect (Fig. 1B) . We have shown previously that mTregs have enhanced suppressor activity in vitro following preactivation with anti-CD3 and IL-2 and that preactivated Tregs did not require reactivation via their TCRs to mediate suppression (23) . Similarly, preactivated hTregs were as suppressive as fresh mTregs for inhibiting the proliferation of mouse CD4 ϩ (Fig. 1C ) and CD8 ϩ ( Fig. 1D) T cells in the absence of restimulation by anti-hCD3/ CD28 in the coculture. Although the suppressive function of preactivated hTregs was comparable to fresh mTregs, they were less suppressive when compared with preactivated mTregs. The reason for this difference is unclear, but is likely due to mechanisms of suppression that might be operative only within species such as IL-2 consumption. The majority of in vitro studies of mouse and human Tregs have shown that the Treg-mediated suppression was not due to IL-10 or ϩ CD25 Ϫ T cells alone or cultured with varying numbers of preactivated hTregs (act.hCD25 high ) from healthy donor D1 or LAD-1 patient P2. Upper panel represents FOXP3 staining of 48-h preactivated hTregs. In these assays, the mouse responders were stimulated with mAPCs and soluble anti-mCD3 while the fresh hTregs were optimally activated with plate-bound anti-hCD3/CD28. The preactivated hTregs were not restimulated.
Ϫ T cells from a normal donor alone (f) or with 1:1 ratio of fresh hTregs (u) from healthy donors (D1/D2) or LAD-1 patients (P1/P2). In this assay, the human responders and Tregs were stimulated with human APCs and soluble anti-hCD3. Data are representative of two independent experiments. Asterisk ‫)ء(‬ represents p Ͻ 0.05 for the differences in suppression between healthy donors and LAD-1 patients.
TGF-␤. Since human IL-10 and TGF-␤ can act on mouse cells, we attempted to reverse the suppressive effects of preactivated hTregs by the addition of neutralizing anti-human IL-10 or anti-TGF-␤ mAbs. Neutralization of TGF-␤ and/or IL-10 and blocking the mouse IL-10 receptor did not abrogate suppression by hTregs (Fig.  1E) . The suppressive effects of the hTregs on mouse responder cells were not even reversed at a concentration of anti-TGF-␤ mAb (50 g/ml) that almost completely neutralized the suppressive effect of 2 ng/ml TGF-␤1 on T cell proliferation (data not shown). rhLAP, a potent neutralizer of TGF-␤ (24), also did not have any effect. Although human CTLA-4 can bind mouse CD80/CD86 (25) and some studies have implicated CTLA-4 on the Tregs as a mediator of their suppressive function either by an unknown mechanism (26) or by induction of the IDO/tryptophan catabolism pathway (13) , selective blocking of the CTLA-4 on the hTregs with anti-hCTLA-4 mAb did not abrogate suppression in the humanmouse assay (Fig. 1E) .
LFA-1 on human Tregs is essential for cell contact-mediated suppression
Previous studies of Tregs have suggested that cell contact between the Tregs and the responder T cells or APCs was necessary for Tregs to mediated suppression. The human-mouse suppression assay offers the unique opportunity to directly determine the contribution of cell surface Ags to cell contact-mediated suppression since we can use reagents directed to the hTregs without interfering with the activation of the mouse responders or the hTregs. One obvious candidate for a receptor/counterreceptor pair that would mediate the interaction of Tregs with their target cells would be LFA-1/ICAM-1 that mediates interactions between almost all immune cells (27, 28) . One previous study (29) using CD18-deficient (Ϫ/Ϫ) mTregs concluded that LFA-1 was required for Treg contact-mediated suppression. However, this study could not distinguish whether LFA-1 was required for Treg interaction with their target cells or whether LFA-1 also was required for activation of the suppressive function of Tregs by the TCR stimulus in association with APCs. Because the fresh hTregs in our model are activated with plate-bound anti-CD3/CD28, we can directly assess whether the interaction between the hTregs and the mouse cells involves the LFA-1/ICAM-1 pathway. Since LFA-1 consists of CD11a and CD18 subunits, the addition of blocking anti-hCD11a or anti-hCD18 mAbs completely abrogated the capacity of freshly explanted human Tregs to suppress mouse responders (Fig. 2A) . The addition of anti-hICAM-1, anti-hICAM-2, and anti-hICAM-3 mAbs did not reverse suppression, ruling out the possibility that the loss of suppression by blocking LFA-1 was due to the inhibition of LFA-1-ICAM-1 interactions between the hTregs. The suppressive capacity of preactivated human Tregs in the absence of anti-hCD3/CD28 restimulation was also abrogated, although not completely, by the addition of anti-hCD11a, therefore making it unlikely that LFA-1 engagement was required during the activation of the hTregs (Fig. 2B) . Multiple mAbs to hCD11a and hCD18 that had been previously characterized as blocking human LFA-1-ICAM-1 interactions also reversed the suppressive effects of hTregs, while mAb MEM-83 (anti-hCD11a) that has been reported to be nonblocking and to increase the high-affinity conformation of LFA-1 (30) did not abrogate hTreg function (Fig. 2C) . Further evidence in support of the binding of hLFA-1 to mICAM-1 was our finding that both fresh and preactivated mouse Tregs failed to significantly suppress human CD4 ϩ T cells (Fig. 2D ), since it has been shown that hLFA-1 can bind mICAM-1 and mI-CAM-2, while the reverse does not occur (31, 32) . Therefore, the lack of suppression by mTregs on human responders was due to the inability of mouse LFA-1 to interact with human ICAM-1.
To eliminate the possibility that the abrogation of suppression by anti-hCD11a or anti-hCD18 mAbs was secondary to a mAbinduced negative signal, we also tested Tregs from leukocyte adhesion deficiency type 1 (LAD-1) patients who have mutations in the CD18 gene that result in a complete deficiency of LFA-1 expression. Fresh (Fig. 3A) and preactivated (Fig. 3B ) Tregs from LAD-1 patients that expressed levels of FOXP3 comparable to normal controls failed to suppress the proliferation of mouse responders. Moreover, Tregs from LAD-1 patients are significantly less suppressive on human CD4 ϩ CD25 Ϫ (Fig. 3C ) or CD8 ϩ T cells (Fig. 3D ) when compared with Tregs from healthy donors. The residual suppression by the Tregs from the LAD-1 patients may indicate that other cell interaction pathways (CD2/CD58, VLA-4/VCAM-1, etc.) may be operative in the interaction of hTreg with hCD4 ϩ CD25 Ϫ T cells or APCs, that a soluble molecule may mediate suppression, or that IL-2 consumption may be playing a role.
hTregs mediate their suppressive function by targeting the mouse DCs via a hLFA-1-mICAM-1-dependent interaction
The cell(s) targeted by Treg-mediated suppression either in vitro or in vivo remains unclear. In the widely used in vitro suppression assays, it has been difficult to determine whether the Tregs acted on the APCs, the CD4 ϩ T cells, or both. Some studies with mTregs (33) and with hTregs (19) have demonstrated suppressor activity when anti-CD3/CD28 beads, plate-bound mAbs, or peptide-MHC tetramers were used as stimuli in APC-free systems. The requirement for a LFA-1-ICAM-1 interaction in the human-mouse suppression assay permits the opportunity to pinpoint the target cell for the suppressor effects of the Tregs. To address whether the hTregs targeted mCD4 ϩ T cells or the mAPCs, we cultured CD4 ϩ CD25 Ϫ T cells from ICAM-1 Ϫ/Ϫ mice in the presence of wildtype T-depleted splenocytes (Fig. 4A) or purified splenic DCs (Fig.  4B) and hTregs. The proliferative responses of CD4 ϩ CD25 Ϫ T cells from ICAM-1 Ϫ/Ϫ mice were still inhibited by the hTregs and abrogated by anti-hCD11a. Suppression also was maintained in the presence of a blocking mAb to mICAM-2 that could potentially interact with human LFA-1 in place of mICAM-1 (Fig. 4, A and  B) . Suppression in this culture system can therefore be mediated solely by an interaction of hLFA-1 expressed on hTregs with mI-CAM-1 expressed on mDCs and not the mouse responder CD4 ϩ T cells deficient in ICAM-1. We were not able to directly use ICAM-1 Ϫ/Ϫ mDCs, since LFA-1-ICAM-1 interactions between the mDCs and mCD4 ϩ T cells were required for activation of the mouse T cells.
To determine whether the interaction of the hTregs on mDCs modulated their function, we cultured the mouse splenic DCs for 18 h in the presence or absence of preactivated hTregs and measured the expression of CD80/CD86 on the DCs. Mouse DCs from wild-type, but not ICAM-1 Ϫ/Ϫ , mice cultured with preactivated hTregs failed to up-regulate CD80/CD86 expression (Fig. 4C) . Preactivated human CD4 ϩ CD25 Ϫ T cells had no effect on the expression of CD80/CD86 on mDCs. Furthermore, preactivated hTregs from LAD-1 patients also failed to suppress the up-regulation of CD80/CD86 expression on wild-type mDCs (Fig. 4D) . No changes in the levels of CD40 or MHC class II expression were seen when the mDCs were cultured with the preactivated hTregs (data not shown). Similarly, preactivated hTregs from healthy donors, but not LAD-1 patients, were able to suppress the up-regulation of CD80/CD86 on human CD19 ϩ B cells stimulated for 36 h with LPS (supplemental Fig. 1  4 ) . To test whether the mDC functions were impaired by their interaction with hTregs, they were purified following the 18-h culture with the different human T cell populations and tested for their ability to present peptide Ag to mouse CD4 ϩ
CD25
Ϫ responder T cells from mice expressing a 4 The online version of this article contains supplemental material. transgenic TCR specific for a peptide from influenza HA. mDCs that had been precultured with hTregs from healthy donors were significantly less efficient at stimulating proliferation and inducing up-regulation of CD69 and CD25 expression on mouse HA-TCR Tg responder T cells as compared with the mDCs cultured alone (Fig. 5) . On the other hand, the mDCs cultured with hCD4 ϩ CD25 Ϫ T cells from healthy donors or hTregs from LAD-1 patients had enhanced activity and increased capacity to activate mouse responders. Taken together, these results indicate that hTregs target mDCs via a critical LFA-1/ICAM-1-dependent interaction, resulting in the inhibition of CD80/CD86 up-regulation and decreased capacity to present Ags to responder T cells.
IL-2 is required for activation of hTreg suppressor function under suboptimal stimulatory conditions, but IL-2 consumption plays no role in hTreg-mediated suppression
Our previous study had demonstrated that IL-2 production by responder T cells is critical for activation of mouse Treg suppressor function (34) . Since both IL-2 and anti-CD25 blocking Abs are currently being used in certain human diseases, it is imperative to address the function of IL-2 signaling in hTregs. Under suboptimal stimulatory condition with anti-hCD3/CD28, highly purified hTregs failed to suppress mouse responders unless a small amount of exogenous human IL-2 (0.5 U/ml) was added to the coculture (Fig. 6A) . However, under the same stimulatory conditions, a less purified hTreg population was able to suppress the mouse responders presumably due to the production of IL-2 by the contaminating human CD4 ϩ CD25 ϩ FOXP3 Ϫ population. This suppression was abrogated by a blocking anti-human CD25 (Fig. 6B) . In contrast, IL-2 was not required for hTreg suppressor function when the hTregs were activated with optimal anti-hCD3/CD28 stimulation (Fig. 6C) and suppression was not reversed by the addition of anti-CD25.
Although most studies demonstrate that the major effect of Tregs on responder CD4 ϩ CD25 Ϫ T cells is to inhibit their capacity to produce IL-2 (5, 35), one of the long-standing controversies concerning the Treg suppression assay is whether some of the suppression seen in the cocultures is secondary to absorption and consumption of IL-2 by the Tregs (17) resulting in cytokine deprivation of the responder CD4 ϩ T cells (16). Because both fresh and preactivated hTregs expressed very high levels of CD25, it was important to determine the potential 
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Ϫ T cells alone (f) or with 1:1 ratio of preactivated hTregs (act.hCD25 high ; u) in the presence of isotype or daclizumab (anti-hCD25). In these assays, the mouse responders were stimulated with mAPCs and soluble anti-mCD3, while the fresh hTregs were stimulated either under suboptimal (3 g/ml anti-hCD3 and 1 g/ml anti-hCD28 plate-bound mAbs) or optimal stimulatory condition (5 g/ml anti-hCD3 and 2.5 g/ml antihCD28 plate-bound mAbs) in the cocultures. The preactivated hTregs were not restimulated in the cocultures. Data are representative of three independent experiments. Asterisk ‫)ء(‬ represents p Ͻ 0.05 for the difference between the black and gray bars in each group.
contribution of the consumption of mIL-2 to the suppressor function of the hTregs in our cocultures. Although it is generally believed that human T cells cannot utilize mIL-2, human T cells can respond to mIL-2 albeit with a 6-to 180-fold lower efficiency than hIL-2 (36). The hTreg-mCD4 ϩ CD25 Ϫ coculture system allows us to directly evaluate the role of consumption of mIL-2 as a major mechanism of Treg suppression. The addition of a high concentration of daclizumab, a humanized mAb to CD25 that blocks the binding of IL-2 to its receptor, failed to reverse the suppressive functions of the optimally activated fresh (Fig. 6C) and preactivated (Fig. 6D) hTregs. The concentrations of daclizumab used were shown to be highly effective at blocking the activation of human T blasts to stimulation by exogenous IL-2 (data not shown). Since activated mouse T cells can use hIL-2 almost as efficiently as activated human T cells, we determined the capacity of fresh or preactivated mTregs, activated with plate-bound anti-mCD3/CD28, to suppress hCD4 ϩ
Ϫ T cells stimulated by hAPCs and anti-hCD3. Although hTregs readily suppressed human responders, we did not observe any appreciable suppression of human CD4 ϩ T cells by mTregs (Fig. 2D ). This result is consistent with our anti-hCD25 blocking studies and directly demonstrates that IL-2 consumption is not a major component of hTreg-mediated suppression.
Discussion
Most studies of Treg function in vitro have suggested that a physical interaction between either the Treg and the responder T cell or the APC was required for suppression, yet little data have been obtained as to the nature of the cell surface Ags involved in these interactions. One of the difficulties in the analysis of this aspect of Treg function in vitro is that many of the potential cellular interaction molecules are also involved in the activation of the T effector cells and it has been difficult to separate out the Treg-specific components. To address this issue, we have developed a novel cross-species suppression assay in which we have shown that hTregs are quite efficient in their ability to suppress mouse responder T cells in the presence of mouse APCs. This assay required cell contact between the hTregs and the mouse cells, as it was not seen across a Transwell (data not shown). The major advantage of this model is that we could target reagents to the hTregs that would not interfere with the activation of the mouse effector cells. Although we initially tested a large panel of anti-human mAbs for their ability to reverse the suppressor function of hTregs, only mAbs against the hLFA-1 heterodimer (CD11a/CD18) reproducibly abrogated suppression. It is unlikely that hLFA-1-hICAM interactions were involved in this assay since the hTregs were activated with plate-bound Abs and anti-hICAM reagents did not reverse suppression. We then took advantage of two different genetic deficiencies, ICAM-1 Ϫ/Ϫ T cells from mice and hTregs from LAD-1 patients with mutations in CD18. hTregs readily inhibited the activation of CD4 ϩ T cells from ICAM-1 Ϫ/Ϫ mice in the presence of wild-type APCs and hTregs from LAD-1 patients failed to inhibit the activation of responder T cells and APCs from wildtype mice. We do not believe that the Tregs from LAD-1 patients are defective during development in the thymus and periphery, which would negatively affect their intrinsic suppressive function. Although there appears to be a decrease in T cell in LFA-1 knockout mice (29) , LAD-1 patients have an increased number of T cells, particularly Tregs. Although CD4 ϩ T cells from healthy donors contain 5-10% FOXP3 ϩ cells, CD4 ϩ T cells from LAD-1 patients have 15-50% FOXP3 ϩ T cells in their peripheral blood (supplemental Fig. 2) . Although the Treg phenotype of the FOXP3 ϩ cells from LAD-1 patients appears to be similar to that of healthy donors with high expression of CD25 and CTLA-4 and low expression of CD127, their inability to suppress may also be secondary to factors other than the absence of LFA-1. Taken together, these studies demonstrate that hTregs mediate the suppression of mouse T cell activation by targeting mDCs. We confirmed this finding by demonstrating that culture of preactivated hTregs with mouse DCs in the absence of responder T cells impaired the ability of the DCs to up-regulate the costimulatory molecules, CD80/CD86, and markedly diminished the subsequent capacity of the hTreg-exposed mDCs to activate responder T cells.
We have not yet excluded the possibility that hTregs are also capable of interacting with mouse responder T cells in addition to mAPCs. This problem is difficult to address because the activation of most T cell responses requires a LFA-1-ICAM-1-dependent interaction between the responder T cells and APCs. We have previously shown that mTregs can inhibit the activation of mouse CD8 ϩ T cells activated by peptide-MHC class I tetramers (18) in the absence of mAPCs, but it remains unclear whether the tetramers directly activate the CD8 ϩ T cells or whether activation of the responder CD8 ϩ T cells also involves a cell-cell interaction. In preliminary studies, the responses of mouse CD8
ϩ T cells to tetramer stimulation were inhibited by preactivated hTregs, but also inhibited by anti-mLFA-1 or anti-mICAM-1, strongly suggesting that cell-cell interactions are involved in the response to tetramer stimulation (data not shown). The mechanism of suppression of CD8 ϩ T cells may be different from that of CD4 ϩ T cells. We have previously demonstrated that mTregs fail to inhibit the responses of mouse CD4 ϩ T cells to stimulation by plate-bound anti-CD3 mAb (23) . Other studies of both mouse and human Tregs have shown that responses to solid-phase anti-CD3 in the absence of APCs can be inhibited by Tregs, but in general significant suppression is only observed at high (1:1) Treg:responder ratios. Although hTregs were able to suppress mouse responders stimulated by mAPCs, the hTregs failed to suppress mouse responders in an APC-free system stimulated by anti-mCD3/CD28-conjugated beads (supplemental Fig. 3 ). In this APC-free system, we did observe some suppression by mTregs but only at a 1:1 and 2:1 ratio of responder:suppressor. It remains possible that Tregs utilize a completely distinct mechanism to directly suppress responder cells under these conditions of stimulation. IL-2 consumption by the Tregs may be very important when T cells are stimulated in the absence of APCs and may ultimately lead to the death of the responder T cells due to cytokine deprivation (16) . However, IL-2 consumption does not appear to play a significant role in the ability of hTregs to suppress mouse responder T cells stimulated by soluble anti-CD3 in the presence of mAPCs, as anti-hCD25 had no effect on Treg suppression.
Tregs have been reported to inhibit the maturation of bone marrow-derived or splenic DCs by modulating the expression of costimulatory molecules (37, 38) or the induction of inhibitory molecules (13, 39), but also have been shown to inhibit T cell responses by fully mature DCs both in vivo (40) and in vitro (41). Ag-specific Tregs have been shown to prevent the interaction between effector T cells and DCs (20, 42) . Ag-specific TGF-␤-induced Tregs also have been shown to inhibit the expansion of autoreactive effector T cells by acting on DCs and by reducing their ability to present autoantigen in vivo and in vitro (21) . We observed similar results when we cultured mDCs with preactivated hTregs. The hTregs prevented the up-regulation of CD80/CD86 and reduced the ability of the DCs to present peptide Ag to responder T cells. Suppression of DC maturation also required a hLFA-1-mICAM-1 interaction because it was blocked by antihCD11a and hTregs from LAD-1 patients that did not suppress. The molecular basis for the suppression remains to be elucidated, but it can clearly cross species. Our data demonstrate that the first step in the process is likely to be a LFA-1-ICAM-1 interaction. The critical function of LFA-1 on Tregs and their interaction with DCs are supported by two recent publications demonstrating the importance of LFA-1 on Tregs in mouse studies (43, 44) .
From a practical standpoint, we believe that the human-mouse suppression assay has the potential of being more reproducible than the standard human-human in vitro suppression assay for evaluating the function of hTregs, particularly in diseases where the immune system has been perturbed. It allows one to specifically assay hTreg function in the absence of potentially hyperactivated responder T cells that can be present in patients with autoimmune diseases. Since IL-2 consumption plays no role in the assay, it also avoids the potential consumption of IL-2 by CD4 ϩ
CD25
ϩ FOXP3 Ϫ effector T cells that can contaminate CD4 ϩ CD25 ϩ FOXP3 ϩ isolated from patients with ongoing inflammatory processes. A limitation of this assay is that potential restrictions may exist in the participation of other receptor/counterreceptor molecules between species in this system. Thus, we have not evaluated the contribution of other adhesion molecules such as CD2/ CD58 or CD49d (or others) that may also play prominent roles in the interaction of Tregs and APCs (or between responder cells and Tregs) within the species in addition to LFA-1. Therefore, the simultaneous use of the hybrid and the conventional suppression assays might be a better method of evaluating the function of hTregs. From a therapeutic standpoint, the human-mouse assay allows for the development of specific reagents that specifically target hTregs. We have already screened a panel of Abs to human cell surface Ags (OX-40, glucocorticoid-induced TNF receptor, ICOS, or 4-1BB) that have been purported to abrogate the function of Tregs, yet none had any effect on the ability of human Tregs to suppress mouse responders (data not shown). Although antihCD11a or anti-hCD18 abrogated suppression by hTregs, blocking human CTLA-4, CD2/CD58, and Fas ligand or neutralizing human TGF-␤ and IL-10 had no effect. Our studies showing a critical role for CD11a/CD18 for the function of hTregs is supported by a recent publication describing three LAD-1 patients with reversion mutations that resulted in a selective expression of LFA-1 only in their CD8 ϩ T cells (45) . Curiously, all three patients developed chronic inflammatory bowel disease. Typically, LAD-1 patients do not develop autoimmunity even though their Tregs are deficient in LFA-1 because the rest of the T cells also lack LFA-1 and are unable to mount a productive immune response. The development of autoimmunity in these LAD-1 patients with reversion mutations might be due to the inability of the Tregs that lack LFA-1 to suppress the CD8 ϩ T cells that can be fully activated because of their selective expression of LFA-1. Biologics such as efalizumab, a humanized monoclonal anti-CD11a approved for the treatment of psoriasis and in clinical trials for other autoimmune diseases, might have a detrimental effect in some patients, depending on the dosage, by providing greater inhibition of Treg function over effector T cell activation. Evidence for this hypothesis is demonstrated by a recent publication (44) showing that diminished CD18 expression on mTregs resulted in impaired cell-cell contact between Tregs and DCs. These dysfunctional Tregs failed to suppress the pathogenic T cells and promoted the onset and severity of psoriasis.
